NCT06211257Recruiting
Superiority Trial Evaluating Digitalized Information Media for Patients With Advanced Sarcomas Receiving Systemic Treatment.
Phase 3 Superiority Trial Evaluating the Benefit of Dematerialized Information Media for Patients With Advanced Sarcomas Receiving Systemic Treatment for Metastatic or Locally Advanced Disease.
Source: ClinicalTrials.gov · Last updated 18 Mar 2026
Brief summary (registry, in English)
ePPS-2202 is a study designed to evaluate the benefits of a dematerialised personalised care plan (PCP) compared to standard information/PCP for patients with advanced sarcomas receiving systemic treatment. Participants will be randomised to an experimental group or a control group. Patients in the experimental group will receive the dematerialised PCP in addition to the standard PCP while patients in the control group will receive the standard PCP alone. All patients will be followed until the end of second-line treatment, the start of a new line of treatment, or until the 24-month follow-up.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 377 (estimated)
- First submitted
- 8 Jan 2024
- Start date
- 29 May 2024
- Primary completion date
- Jul 2028
- Lead sponsor
- Centre Oscar Lambret
- Diseases
- Sarcoma
- NCT number
- NCT06211257
What you commit to
- Study type: Interventional
- Planned participants: 377
- From 29 May 2024 to the primary completion date, Jul 2028
- 11 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior inclusion in ePPS trial for a prior systemic treatment ;
Other
- Poor understanding of French ;
- Difficulty accessing a computer ;
- Pregnant or nursing woman ;
- Person deprived of liberty or under guardianship ;
- Impossibility of undergoing medical follow-up for geographical, social or psychological reasons.
Who the study is looking for
- Sarcomas of soft tissues or viscera ;
- Inoperable metastatic or locally advanced disease ;
- Indication for systemic treatment with pazopanib, trabectedine, eribulin, ifosfamide or dacarbazine monotherapy ;
- Patient covered by French social security ;
- Written, signed, informed consent ;
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (11)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Chu Jean Minjoz Coordinator of this site? Confirm its status | Besançon | France | Recruiting |
| Centre Oscar Lambret Coordinator of this site? Confirm its status | Lille | France | Recruiting |
| Centre Leon Berard Coordinator of this site? Confirm its status | Lyon | France | Recruiting |
| Hôpital Pitié-Salpêtrière - AP-HP Coordinator of this site? Confirm its status | Paris | France | Not yet recruiting |
| CHU de Poitiers Coordinator of this site? Confirm its status | Poitiers | France | Recruiting |
| Centre Eugène Marquis Coordinator of this site? Confirm its status | Rennes | France | Not yet recruiting |
| Institut de Cancérologie de l'Ouest Coordinator of this site? Confirm its status | Saint-Herblain | France | Recruiting |
| Centre Paul Strauss Coordinator of this site? Confirm its status | Strasbourg | France | Recruiting |
| Institut Claudius Regaud Coordinator of this site? Confirm its status | Toulouse | France | Withdrawn |
| Institut de Cancérologie de Lorraine Coordinator of this site? Confirm its status | Vandœuvre-lès-Nancy | France | Not yet recruiting |
| Gustave Roussy Coordinator of this site? Confirm its status | Villejuif | France | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.